Home LiteratureArticle Details
PMID: 21898694 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products.

Stem cells (Dayton, Ohio) ·Vol. 30 ·No. 1 ·2012-01-00 ·Pages 42-7

Jung Y, Bauer G, Nolta JA

Abstract

Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with "safe harbor" vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.

MeSH Terms
Adult Stem Cells/metabolism,transplantation Animals Cell Differentiation/physiology Cellular Reprogramming/genetics Embryonic Stem Cells/cytology,transplantation Humans Induced Pluripotent Stem Cells/cytology Mesenchymal Stem Cells/cytology Mice Pluripotent Stem Cells/cytology Stem Cell Transplantation Transgenes/genetics
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Jung Yunjoon
Department of Biomedical Engineering, University of California, Davis, Sacramento, California 95817, USA.
Bauer Gerhard
Nolta Jan A
References (61)
61 references, click to expand
  1. Generation of germline-competent induced pluripotent stem cells.
    Nature. 2007 Jul 19;448(7151):313-7 PMID: 17554338
  2. Mesenchymal stromal cells for graft-versus-host disease.
    Hum Gene Ther. 2011 Mar;22(3):257-62 PMID: 21288086
  3. Hematopoietic stem-cell transplantation.
    N Engl J Med. 2006 Apr 27;354(17):1813-26 PMID: 16641398
  4. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.
    Cell. 2006 Aug 25;126(4):663-76 PMID: 16904174
  5. Embryonic stem cell lines derived from human blastocysts.
    Science. 1998 Nov 6;282(5391):1145-7 PMID: 9804556
  6. Geron trial resumes, but standards for stem cell trials remain elusive.
    Nat Biotechnol. 2010 Oct;28(10):989-90 PMID: 20944564
  7. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
    Mol Ther. 2008 Jul;16(7):1308-15 PMID: 18461052
  8. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.
    Adv Drug Deliv Rev. 2010 Sep 30;62(12):1167-74 PMID: 20920540
  9. Optimizing mesenchymal stem cell-based therapeutics.
    Curr Opin Biotechnol. 2009 Oct;20(5):531-6 PMID: 19783424
  10. MSCs: Biological characteristics, clinical applications and their outstanding concerns.
    Ageing Res Rev. 2011 Jan;10(1):93-103 PMID: 20727988
  11. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells.
    Nature. 2011 Mar 3;471(7336):68-73 PMID: 21289626
  12. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity.
    Blood. 2009 May 21;113(21):5340-51 PMID: 19324906
  13. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.
    PLoS Med. 2009 Feb 17;6(2):e1000029 PMID: 19226183
  14. Methods for making induced pluripotent stem cells: reprogramming à la carte.
    Nat Rev Genet. 2011 Apr;12(4):231-42 PMID: 21339765
  15. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    J Clin Invest. 2008 Sep;118(9):3132-42 PMID: 18688285
  16. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.
    Stem Cells. 2008 Aug;26(8):2173-82 PMID: 18511601
  17. Mesenchymal stem cells for the treatment of neurodegenerative disease.
    Regen Med. 2010 Nov;5(6):933-46 PMID: 21082892
  18. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    N Engl J Med. 2009 Jan 29;360(5):447-58 PMID: 19179314
  19. Human embryonic stem cell-derived mesenchymal progenitors: an overview.
    Methods Mol Biol. 2011;690:163-74 PMID: 21042992
  20. Induced pluripotent stem cells from a spinal muscular atrophy patient.
    Nature. 2009 Jan 15;457(7227):277-80 PMID: 19098894
  21. Bone marrow stromal cells as a vehicle for gene transfer.
    Gene Ther. 1999 Sep;6(9):1611-6 PMID: 10490771
  22. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial.
    Circulation. 2007 Sep 11;116(11 Suppl):I24-30 PMID: 17846310
  23. Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells.
    Tissue Eng Part A. 2011 Jun;17(11-12):1517-25 PMID: 21275830
  24. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.
    Science. 2007 Dec 21;318(5858):1920-3 PMID: 18063756
  25. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells.
    Cell Stem Cell. 2010 Oct 8;7(4):521-31 PMID: 20887957
  26. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.
    Nat Biotechnol. 2008 Jan;26(1):101-6 PMID: 18059259
  27. Concise review: hitting the right spot with mesenchymal stromal cells.
    Stem Cells. 2010 Aug;28(8):1446-55 PMID: 20597105
  28. Homografts of bone marrow in dogs after lethal total-body radiation.
    Blood. 1959 Jun;14(6):720-36 PMID: 13651344
  29. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells.
    Stem Cells Dev. 2011 Sep;20(9):1549-61 PMID: 21204633
  30. Mesenchymal stem cells as vehicles for gene delivery.
    Clin Orthop Relat Res. 2000 Oct;(379 Suppl):S71-90 PMID: 11039755
  31. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
    Lancet. 2008 May 10;371(9624):1579-86 PMID: 18468541
  32. Cardiac cell therapy: lessons from clinical trials.
    J Mol Cell Cardiol. 2011 Feb;50(2):258-65 PMID: 20600097
  33. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy.
    Stem Cells. 2011 Nov;29(11):1727-37 PMID: 21898687
  34. Reprogramming of human primary somatic cells by OCT4 and chemical compounds.
    Cell Stem Cell. 2010 Dec 3;7(6):651-5 PMID: 21112560
  35. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
    Nature. 2010 Sep 16;467(7313):318-22 PMID: 20844535
  36. FDA regulation of stem-cell-based therapies.
    N Engl J Med. 2006 Oct 19;355(16):1730-5 PMID: 17050899
  37. Transplantation of gene-modified human bone marrow stromal cells into mouse-human bone chimeras.
    J Hematother Stem Cell Res. 2000 Apr;9(2):175-81 PMID: 10813530
  38. Human mesenchymal stem cells modulate allogeneic immune cell responses.
    Blood. 2005 Feb 15;105(4):1815-22 PMID: 15494428
  39. Turning straw into gold: directing cell fate for regenerative medicine.
    Nat Rev Genet. 2011 Apr;12(4):243-52 PMID: 21386864
  40. Mesenchymal stem cell therapy: Two steps forward, one step back.
    Trends Mol Med. 2010 May;16(5):203-9 PMID: 20335067
  41. Self-renewal and differentiation capacity of young and aged stem cells.
    Exp Cell Res. 2008 Jun 10;314(9):1937-44 PMID: 18439579
  42. Copy number variation and selection during reprogramming to pluripotency.
    Nature. 2011 Mar 3;471(7336):58-62 PMID: 21368824
  43. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease.
    Stem Cells. 2008 Jul;26(7):1713-22 PMID: 18436861
  44. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone.
    Nat Med. 2008 Feb;14(2):181-7 PMID: 18193058
  45. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.
    Nat Biotechnol. 2006 Jun;24(6):687-96 PMID: 16732270
  46. Mesenchymal stem cell homing: the devil is in the details.
    Cell Stem Cell. 2009 Mar 6;4(3):206-16 PMID: 19265660
  47. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.
    Nat Med. 1999 Mar;5(3):309-13 PMID: 10086387
  48. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.
    Circulation. 2010 Mar 9;121(9):1113-23 PMID: 20176987
  49. Mesenchymal stem cells as therapeutics.
    Annu Rev Biomed Eng. 2010 Aug 15;12:87-117 PMID: 20415588
  50. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.
    Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5856-61 PMID: 18391196
  51. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture.
    Cell Stem Cell. 2011 Jan 7;8(1):106-18 PMID: 21211785
  52. Disease-specific induced pluripotent stem cells.
    Cell. 2008 Sep 5;134(5):877-86 PMID: 18691744
  53. Epigenetic memory in induced pluripotent stem cells.
    Nature. 2010 Sep 16;467(7313):285-90 PMID: 20644535
  54. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues.
    Cell. 2010 Nov 12;143(4):508-25 PMID: 21074044
  55. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Science. 2003 Oct 17;302(5644):415-9 PMID: 14564000
  56. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells.
    Mol Ther. 2011 Mar;19(3):584-93 PMID: 21119622
  57. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.
    Transplantation. 1974 Apr;17(4):331-40 PMID: 4150881
  58. Somatic coding mutations in human induced pluripotent stem cells.
    Nature. 2011 Mar 3;471(7336):63-7 PMID: 21368825
  59. Stem-cell gene therapy for the Wiskott-Aldrich syndrome.
    N Engl J Med. 2010 Nov 11;363(20):1918-27 PMID: 21067383
  60. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41 PMID: 20457269
  61. Human embryonic stem cells express an immunogenic nonhuman sialic acid.
    Nat Med. 2005 Feb;11(2):228-32 PMID: 15685172
Article Info
Journal
Stem cells (Dayton, Ohio)
Abbr.
Stem Cells
ISSN
1549-4918
DOI
10.1002/stem.727
Published
2012-01-00
Pages
42-7
Language
English
Region
United States
NLM ID
9304532
PMCID
PMC3784250
Subset
IM
Grants
NIA NIH HHS · RC1 AG036022 · United States
NIA NIH HHS · 5RC1AG036022 · United States
NCRR NIH HHS · S10 RR026825 · United States
NIGMS NIH HHS · R01 GM099688 · United States
NHLBI NIH HHS · R01 HL073256 · United States
External Links
PubMed source DOI: 10.1002/stem.727 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2